CAJ | 학술논문

目的探讨腹膜透析治疗进入终末期肾脏病(ESRD)常染色体显性遗传性多囊肾病(ADPKD)患者的可行性及疗效.方法回顾性分析2003年10月至2011年2月期间在本院行腹膜透析治疗的11例ADPKD患者的临床资料.其中6例合并多囊肝,术前经影像学及家系调查确诊.11例均采用外科手术方法进行置管.观察术中术后并发症、导管相关性并发症、腹膜透析相关并发症、尿毒症症状改善情况、生存时间、退出透析或死亡等结局.结果 11例手术均获成功,术中经过顺利,术后均未出现并发症.术后住院时间平均为12天.11例患者术后随访12 ～54个月,平均30个月.随访期间11例患者尿毒症症状均有改善,平均生存时间为31.6个月.1例因腹膜炎拔管重置,1例于透析14个月后转为血液透析治疗,1例因消化道出血死亡,1例因心力衰竭死亡.结论腹膜透析治疗ADPKD患者安全有效,ADPKD患者也可以选择腹膜透析作为初始的肾脏替代治疗.
목적 탐토복막투석치료진입종말기신장병(ESRD)상염색체현성유전성다낭신병(ADPKD)환자적가행성급료효.방법 회고성분석2003년10월지2011년2월기간재본원행복막투석치료적11례ADPKD환자적림상자료.기중6례합병다낭간,술전경영상학급가계조사학진.11례균채용외과수술방법진행치관.관찰술중술후병발증、도관상관성병발증、복막투석상관병발증、뇨독증증상개선정황、생존시간、퇴출투석혹사망등결국.결과 11례수술균획성공,술중경과순리,술후균미출현병발증.술후주원시간평균위12천.11례환자술후수방12 ～54개월,평균30개월.수방기간11례환자뇨독증증상균유개선,평균생존시간위31.6개월.1례인복막염발관중치,1례우투석14개월후전위혈액투석치료,1례인소화도출혈사망,1례인심력쇠갈사망.결론 복막투석치료ADPKD환자안전유효,ADPKD환자야가이선택복막투석작위초시적신장체대치료.
Objectives To investigate the effect and feasibility of peritoneal dialysis ( PD ) on autosomal dominant polycystic kidney disease (ADPKD) patient with end-stage renal disease (ESRD).Methods Clinical data of 11 autosomal dominant polycystic kidney disease ( ADPKD ) patients from October 2003 to Febrary 2011,including 6 patients with polycystic liver disease,diagnosed by iconography and family investigation,were analyzed retrospectively.Peritoneal dialysis tube implanted by means of surgery.We observed intraoperative and poetoperative complications,catheter-related complications,peritoneal dialysis-related complications,uremic symptoms improved,survival times,quit of dialysis or death,ect.Results All patients surgery successfully without intraoperative and postoperative complications.The mean average of hoapital stay was 12 days.During the follow-up of 12 ～ 54months,average survival time was 31.6 months.1 patient with peritonitis,removal of peritoneal dialysis tube and re-implanted,1 patient undergoing hemodialysis after 14 montth,2 patients dead.Conclusions ADPKD patients treated with PD safely and effectivlly,ADPKD patients can choose PD as the initial therapy of ESRD.